Quality Systems – Page 271

Particulate Matter Oos for multi-dose products: sampling, filtration, and EM controls

Investigating Particulate Matter OOS for Multi-Dose Products: Effective Sampling, Filtration, and Environmental Controls Particulate matter contamination in multi-dose pharmaceutical products, particularly ophthalmic formulations, can pose significant challenges to manufacturers. The…

Ccit Failure during terminal sterilization: FDA/MHRA investigation narrative and batch impact

Examining Ccit Failure During Terminal Sterilization: An In-Depth Investigation Narrative Ccit failure during terminal sterilization poses significant challenges within pharmaceutical manufacturing, potentially leading to batch rejections and regulatory scrutiny. Understanding…

Dose Delivery Variability during EU/UK market supply: inspection-ready documentation pack

Dose Delivery Variability Investigation for EU/UK Market Supply: An Organized Approach Variability in dose delivery can significantly impact therapeutic outcomes and regulatory compliance in pharmaceutical manufacturing. In environments such as…

Ph Drift during bulk hold: cleaning validation and worst-case selection

Investigation of pH Drift during Bulk Hold: Cleaning Validation and Worst-Case Selection pH drift during bulk hold presents significant challenges for pharmaceutical manufacturers, particularly within the realm of topical and…

Dose Delivery Variability at accelerated stability: process parameter review and validation impact

Investigation of Dose Delivery Variability During Accelerated Stability Testing In the dynamic environment of pharmaceutical manufacturing, variability in dose delivery during accelerated stability testing can lead to significant quality concerns,…

E&L Failure after packaging change: sampling, filtration, and EM controls

In the highly regulated landscape of pharmaceutical manufacturing, a packaging change can inadvertently lead to Extractables and Leachables (E&L) failures in drug products. Such occurrences pose significant quality risks and…

Curling After Packaging during EU/UK market supply: root cause mapping across materials and process

Root Cause Mapping for Curling in Transdermal Drug Delivery Systems after Packaging The occurrence of curling in transdermal drug delivery systems after packaging can pose significant challenges for pharmaceutical manufacturers,…

Fill Weight Variability after packaging change: GMP investigation and CAPA strategy

Investigation of Fill Weight Variability Following a Packaging Change in Pharmaceutical Manufacturing In pharmaceutical manufacturing, consistency in fill weight is crucial for ensuring product quality and regulatory compliance. Recently, a…

Ivrt Failure during EU/UK market supply: process parameter review and validation impact

Investigating IVRT Failures Impacting EU/UK Market Supply: A Process Review In the pharmaceutical industry, ensuring the efficacy and safety of products is a paramount concern. Among various quality assurance measures,…

Fill Weight Variability during homogenization: GMP investigation and CAPA strategy

Investigating Fill Weight Variability during Homogenization: A GMP Approach In pharmaceutical manufacturing, maintaining consistency in product fill weights is crucial to meet the stringent requirements of regulatory agencies. Fill weight…

Ivpt Failure during EU/UK market supply: process parameter review and validation impact

Investigation of Ivpt Failure in EU/UK Market Supply: Reviewing Process Parameters and Validation Impact In pharmaceutical manufacturing, in vitro permeation testing (IVPT) is crucial for ensuring the efficacy and safety…

Pet Failure during sterile filtration: CAPA and effectiveness check plan

Addressing Pet Failures during Sterile Filtration: An Investigation Approach Pet failures during sterile filtration present significant challenges in pharmaceutical manufacturing, particularly in the production of ophthalmic dosage forms. The inability…